News archive
Showing 692 results
October 2019
-
Media Release
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
In two head-to-head clinical trials, patients on BEOVU (brolucizumab-dbll) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of… -
Media Release
Novartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing
-
Media Release
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
-
Media Release
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
- Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)(1)- Novartis plans FDA submission… -
Media Release
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
September 2019
-
Story Discovery
Word on the Street: What is cell and gene therapy?
We leave the lab to find out what people know about cell and gene therapy.
-
Statement
Form 483 posting by US Food and Drug Administration (FDA) – Novartis statement
-
Media Release
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
BASEL, Switzerland, Sept. 19, 2019 /PRNewswire/ -- New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate… -
Media Release
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
-
Media Release
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
- Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients;(… -
Media Release
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings